TG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors.
In vitro: TG6-10-1, an analog of TG4-155 (a prostaglandin receptor EP2 antagonist, with a relatively short plasma half-life (0.6 h) and low brain: plasma ratio (0.3) after systemic administration in mice), which has a superior pharmacokinetic profile making it suitable for more extensive testing. TG6-10-1 had negligible effect on a panel of 40 enzymes, ion channels, receptors, and neurotransmitter transporters (IC50s > 10 μM), except that TG6-10-1 weakly inhibited the serotonin 5-hydroxytryptamine 2B (5-HT2B) receptor with IC50 = 7.5 μM. At a high concentration (10 μM), TG6-10-1 had little or no effect on the enzymatic activity of COX-1 (7% inhibition) and COX-2 (14% inhibition), and inhibited the leukotriene B4 (LTB4) receptor BLT1 by 1%. TG6-10-1 has a competitive mechanism of antagonism of the EP2 receptor with an equilibrium dissociation constant for the antagonist-receptor complex (KB) of 17.8 nM.
In vivo: TG6-10-1 displayed a plasma half-life of 1.6 h and a brain: plasma ratio of 1.6 after systemic administration (5 mg/kg, i.p.) in mice.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 10 mM|
Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus.
Rojas A, et al. Neuropharmacology. 2015 Jun;93:15-27. PMID: 25656476.
Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.
Jiang J, et al. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3591-6. PMID: 23401547.
|Related 5-HT Receptor Products|
LY344864 is a selective 5-HT1F receptor agonist with an affinity of 6 nM (Ki).
YL-0919 is a novel 5-HT1A receptor agonist and selective serotonin reuptake inhibitor.
8-OH-DPAT (8-Hydroxy-DPAT) is a potent and selective 5-HT agonist, with a pIC50 of 8.19 for 5-HT1A.
Idalopirdine hydrochloride is a potent and selective 5-HT6 receptor antagonist with a Ki value of 0.83 nM.
PRX-08066 is a a novel 5-hydroxytryptamine receptor 2B antagonist with IC50 of 3.4 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.